Viridian Therapeutics Reports Positive VRDN-008 Phase 1 Results Supporting Potential Every-Eight-Week Dosing

• Viridian Therapeutics announced positive phase 1 results for VRDN-008, supporting potential subcutaneous dosing every eight weeks.
• The healthy-volunteer trial showed deep, sustained IgG suppression with generally favorable tolerability and no serious adverse events or dose-limiting toxicities.
• A registrational trial in MG is planned for mid-2027, pending regulatory feedback.
• The trial would compare dosing every four weeks or eight weeks against placebo, using the enFuse on-body injector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261109277578) on November 09, 2026, and is solely responsible for the information contained therein.